Related Experiment Video
Updated: Jul 1, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
Menthol inhalation relieves dyspnoea through the brain
Lucas Vanden Bossche1, Samantha Piers1, Michele R Schaeffer2
1Research Group Health Psychology, KU Leuven, Leuven, Belgium.
Background:
Menthol inhalation (MI) relieves dyspnoea in healthy individuals and people with respiratory disorders, independent of changes in breathing patterns and respiratory muscle electromyography activity. Thus, the underlying working mechanism of MI is unknown. We tested whether MI reduces dyspnoea by attenuating the neural processing of afferent respiratory sensations, without altering respiratory patterns and the efferent neural drive to breathe.
Methods:
Thirty healthy adults completed four 5-min trials of strong inspiratory resistive loaded breathing: two with MI and two with strawberry scent inhalation (SI; placebo control), in counterbalanced order. Paired inspiratory occlusions (150 ms) were randomly administered every 2-6 breaths to evoke respiratory-related evoked potentials (RREPs) in the electroencephalogram, reflecting neural processing of respiratory signals. Respiratory parameters were measured continuously, and neural drive to breathe was assessed via inspiratory occlusion pressure (P0.1). Dyspnoea intensity and unpleasantness were rated using the modified Borg scale, and five sensory dyspnoea qualities were rated using the Multidimensional Dyspnoea Profile.
Results:
Dyspnoea intensity (Δ=-0.67 modified Borg units, p=0.003, d=-0.56), air hunger (p<0.001), and mental breathing effort (p=0.004) were lower with MI compared with SI. The RREP P2 mean amplitude was lower with MI (Δ=-1.51 µV, p=0.04, d=0.38), and exploratory analysis revealed an additional reduced "P3frontal" RREP component (p=0.04). Respiratory parameters and P0.1 showed only minor differences between conditions.
Conclusions:
MI relieved dyspnoea with concurrent changes in the neural processing of respiratory sensations, in the absence of meaningful changes in respiratory patterns or neural drive to breathe. This suggests that MI relieves dyspnoea via a neural mechanism.
Related Concept Videos
Inhaled Medications
COPD: Management Using Bronchodilators and Corticosteroids
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Hyperpnea and Hyperventilation
Physiological Control of Respiration
Breathing, a seemingly passive process, is regulated by the respiratory center in the brainstem. This center coordinates the involuntary control of respirations, which means it occurs without conscious effort, ensuring a smooth and uninterrupted pattern.
Regulation of Ventilation
The body maintains ventilation by monitoring levels of carbon dioxide (CO2), oxygen (O2), and hydrogen ion concentration (pH) in the arterial blood. Among these factors, the level of CO2 plays a crucial...
Antiasthma Drugs: Methylxanthines
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
